Drug Profile
Research programme: bacterial vaccines - sanofi/Valneva
Alternative Names: Bacterial vaccines research programme - sanofi/ValnevaLatest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator Intercell; sanofi pasteur
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Austria
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in France
- 28 May 2013 Intercell has merged with Vivalis to form Valneva